Jiudian Pharmaceutical (300705.SZ) intends to acquire 10% equity of Nona Medicine to consolidate its controlling position.

Zhito Finance and Economics APP News, Jiudian Pharmaceutical (300705.SZ) announced that the company plans to use its own funds of 46.5845 million yuan to acquire 10% equity of Nona Medicine held by Shangshan Hongren. After the transaction is completed, the company's shareholding in Nona Medicine will increase from 60% to 70%, and Nona Medicine will remain a subsidiary controlled by the company. The related matters aim to consolidate the controlling position of Nona Medicine and further deepen the company's strategic layout in the field of biomedicine.